Abstract:Porcine reproductive and respiratory syndrome (PRRS) is an economically devastating respiratory disease of pigs. The disease is caused by the PRRS virus (PRRSV), an Arterivirus which is a highly mutating RNA virus. Widely used modified live PRRSV vaccines have failed to prevent PRRS outbreaks and reinfections; moreover, safety of the live virus vaccines is questionable. Though poorly immunogenic, inactivated PRRSV vaccine is safe. The PRRSV infects primarily the lung macrophages. Therefore, we attempted to strengthen the immunogenicity of inactivated/killed PRRSV vaccine antigens (KAg), especially in the pig respiratory system, through: 1) entrapping the KAg in biodegradable poly(lactic-co-glycolic acid) nanoparticles (NP-KAg); 2) coupling the NP-KAg with a potent mucosal adjuvant, whole cell lysate of Mycobacterium tuberculosis (M. tb WCL); and 3) delivering the vaccine formulation twice intranasally to growing pigs. We have previously shown that a single dose of NP-KAg partially cleared the challenged heterologous PRRSV. Recently, we reported that NP-KAg coupled with unentrapped M. tb WCL significantly cleared the viremia of challenged heterologous PRRSV. Since PRRSV is primarily a lung disease, our goal in this study was to investigate lung viral load and various immune correlates of protection at the lung mucosal surfaces and its parenchyma in vaccinated heterologous PRRSV-challenged pigs. Our results indicated that out of five different vaccine-adjuvant formulations, the combination of NP-KAg and unentrapped M. tb WCL significantly cleared detectable replicating infective PRRSV with a tenfold reduction in viral RNA load in the lungs, associated with substantially reduced gross and microscopic lung pathology. Immunologically, strong humoral (enhanced virus neutralization titers by high avidity antibodies) and cell-mediated immune responses (augmented population of interferon-γ secreting CD4(+) and CD8(+) lymphocytes and reduced secretion of immunosuppressive cytokines) in the lungs were observed. In conclusion, combination of NP-KAg and soluble M. tb WCL elicits broadly cross-protective anti-PRRSV immunity in the pig respiratory system.

Expression of the nucleocapsid protein of porcine reproductive and respiratory syndrome virus in soybean seed yields an immunogenic antigenic protein

A transgenic Marc-145 cell line of piggyBac transposon-derived targeting shRNA interference against porcine reproductive and respiratory syndrome virus.

Generation and immunogenicity of transgenic potato expressing the GP5 protein of porcine reproductive and respiratory syndrome virus

Boosting in planta production of antigens derived from the porcine reproductive and respiratory syndrome virus (PRRSV) and subsequent evaluation of their immunogenicity

Porcine Reproductive and Respiratory Syndrome Virus Engineered by Serine Substitution on the 44th Amino Acid of GP5 Resulted in a Potential Vaccine Candidate with the Ability to Produce High Levels of Neutralizing Antibody

Immune Responses of Pigs Immunized with a Recombinant Porcine Reproductive and Respiratory Syndrome Virus Expressing Porcine GM-CSF.

The mRNA Vaccine Expressing Single and Fused Structural Proteins of Porcine Reproductive and Respiratory Syndrome Induces Strong Cellular and Humoral Immune Responses in BalB/C Mice

Immunogenicity of the highly pathogenic porcine reproductive and respiratory syndrome virus GP5 protein encoded by a synthetic ORF5 gene

Development of a Porcine Reproductive and Respiratory Syndrome Virus-Like-particle-based Vaccine and Evaluation of Its Immunogenicity in Pigs.

Immunogenicity and Protective Efficacy of Recombinant Pseudorabies Virus Expressing the Two Major Membrane-Associated Proteins of Porcine Reproductive and Respiratory Syndrome Virus

Oral Bacillus subtilis spores-based vaccine for mass vaccination against porcine reproductive and respiratory syndrome

Adsorption of a Porcine Reproductive and Respiratory Syndrome Virus DNA Vaccine Candidate Onto Biodegradable Nanoparticles Improves Immunogenicity in Mice

Development of a Vaccine Vector Based on a Subgenomic Replicon of Porcine Reproductive and Respiratory Syndrome Virus

Humoral Immune Response Induced by Oral Administration of S. Typhimurium Containing a DNA Vaccine Against Porcine Reproductive and Respiratory Syndrome Virus.

Enhanced immunogenicity of the modified GP5 of porcine reproductive and respiratory syndrome virus

Highly Efficient Expression of Interleukin-2 under the Control of Rabbit Beta-Globin Intron Ii Gene Enhances Protective Immune Responses of Porcine Reproductive and Respiratory Syndrome (prrs) Dna Vaccine in Pigs

An Innovative Approach to Induce Cross-Protective Immunity Against Porcine Reproductive and Respiratory Syndrome Virus in the Lungs of Pigs Through Adjuvanted Nanotechnology-Based Vaccination

Immunogenicity of the Glycoprotein 5 Truncated Trans-Membrane Regions of Porcine Reproductive and Respiratory Syndrome Virus

Construction and Optimization of Lactobacillus Plantarum Expression System Expressing Glycoprotein 5 of Porcine Reproductive and Respiratory Syndrome Virus.

Expression of Fusion Protein of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) GP3-GP5-M in PK-15 Cells

Porcine GPX1 enhances GP5-based DNA vaccination against porcine reproductive and respiratory syndrome virus